Voyager Therapeutics

Yahoo Finance • 7 days ago

Advanced Viral Delivery Systems Revolutionizing Gene Therapy for Neurological Disorders

Dublin, Oct. 06, 2025 (GLOBE NEWSWIRE) -- The "Gene Therapy on Neurological Diseases Market Report 2025" has been added to ResearchAndMarkets.com's offering. The gene therapy on neurological diseases market size has grown rapidly in... Full story

Yahoo Finance • 2 months ago

Voyager to Present at Upcoming Investor Conferences

LEXINGTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in... Full story

Yahoo Finance • 2 months ago

Voyager Reports Second Quarter 2025 Financial and Operating Results

- Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs - - APOE program added to pipeline; fourth asset in industry-leading Alzheimer’s disease franchise - - 11 partnered programs with potential... Full story

Yahoo Finance • 3 months ago

Baird reiterates Outperform rating on Voyager Therapeutics stock with $18 price target

Investing.com - Baird maintained its Outperform rating and $18.00 price target on Voyager Therapeutics (NASDAQ:VYGR) stock following an in-person meeting with company management. According to InvestingPro data, the stock is currently tradi... Full story

Yahoo Finance • 3 months ago

Sector Update: Health Care Stocks Climb Late Afternoon

Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index adding 1.1% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 3 months ago

Voyager Therapeutics unveils APOE-targeting Alzheimer's therapy program

LEXINGTON, Mass. - Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company whose stock has declined over 45% year-to-date according to InvestingPro data, on Wednesday announced a new gene therapy program targeting a... Full story

Yahoo Finance • 3 months ago

Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach

- New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant - - Voyager’s wholly-owned Alzheimer’s disease franchise... Full story

Yahoo Finance • 4 months ago

Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

LEXINGTON, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced Alfred W. Sandrock, Jr., M.D., Ph.D.,... Full story

Yahoo Finance • 5 months ago

Voyager Reports First Quarter 2025 Financial and Operating Results

– Tau silencing gene therapy VY1706 to be featured in oral presentation at ASGCT 2025; has shown up to 73% knockdown of tau mRNA in the CNS in NHPs following a single IV dose of 1.3e13 vg/kg – – Recent Voyager data on VY7523 and VY1706 pr... Full story

Yahoo Finance • 6 months ago

Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025

- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical murine data strengthen case for specific... Full story

Yahoo Finance • 7 months ago

Bragar Eagel & Squire, P.C. Is Investigating Dave, Red Cat, Perpetua, and Voyager and Encourages Investors to Contact the Firm

NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Dave, Inc. (NASDAQ: DAVE), Red Cat Holdings, Inc. (NASDAQ: RCAT), Pe... Full story

Yahoo Finance • 7 months ago

Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

- Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 - - Anti-tau antibody VY7523was well tolerated in healthy volunteers and sh... Full story

Yahoo Finance • 7 months ago

Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast

LEXINGTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fourth quarter 2024 financial and opera... Full story

Yahoo Finance • 7 months ago

Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer’s Disease

- Topline SAD data from healthy volunteers demonstrate safety, tolerability, and dose-proportional pharmacokinetics, supporting potentially best-in-class profile - - MAD study initiated in patients with early Alzheimer’s disease; initial... Full story

Yahoo Finance • 8 months ago

VOYAGER ALERT: Bragar Eagel & Squire, P.C. is Investigating Voyager Therapeutics, Inc. on Behalf of Voyager Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Voyager Therapeutics, Inc. (“Voyager” or the “Company”) (NASDAQ:VYGR)... Full story

Yahoo Finance • 8 months ago

Kirby McInerney LLP Announces Investigation Against Voyager Therapeutics, Inc. (VYGR) on Behalf of Investors

NEW YORK, Feb. 19, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Voyager Therapeutics, Inc. (“Voyager” or the “Company”) (NASDAQ:VYGR). The investigation concerns whether Voyager a... Full story

Yahoo Finance • 2 years ago

12 Best Healthcare Stocks For the Long-Term

In this piece, we will take a look at the 12 best healthcare stocks for the long term. If you want to skip our overview of the healthcare industry, then you can take a look at 5 Best Healthcare Stocks For the Long-Term. The healthcare ind... Full story

Yahoo Finance • 2 years ago

Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results

- GLP toxicology studies initiated for VY-TAU01 anti-tau antibody for Alzheimer’s disease to enable anticipated 1H 2024 IND filing - - SOD1 ALS gene therapy program on track for development candidate selection by end of year – - Conferen... Full story

Yahoo Finance • 2 years ago

Voyager Therapeutics Announces Third Quarter 2023 Conference Call and Webcast

CAMBRIDGE, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced it will report third quarter 2023... Full story

Yahoo Finance • 2 years ago

Voyager Therapeutics to Present at the Chardan Genetic Medicines Conference

CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that Chief Executive Officer Al... Full story